Tissue Micro Arrayer
Analyzing Tissue from Clinical Practice to Medical Research
      Tissue microarray (TMA) is not just another tool for pathologists.
TMA is :
 - An effective quality assurance tool for diagnostics
 - Used as positive staining controls for antibody validation
 - Widely used to analyze gene expression in multiple pathological samples

As the US President Obama unveiled the Precision Medicine Initiative (PMI), we must gain insights into the individual variability in genes as well as the subtypes of diseases based on the molecular and cellular analysis. 

Technologies such as DNA microarrays allow researchers to examine the changes in the genome (DNA), transcription (mRNA), proteome (proteins), or metabolome (metabolites) in order to understand the physiology and mechanism of disease. In particular, the application of DNA microarray has led to the comprehension of the molecular and pathophysiological characteristics of an individual patient and tumor. However, the large volumes of data produced by DNA microarrays require further validation, which can be both time-consuming and expensive. Tissue microarrays (TMAs) have become the predominant clinical research tool for validation tools from DNA microarray-based gene expression profiling as it can mimic the real-world clinical samples by treating hundreds of tissues as one sample.
As DNA microarrays and TMAs provide deeper understanding of cancer biology and uncover new sub-classifications of cancer and likely patient responses - all of which influence new courses of treatment and future drug design. The TMA techniques have been in use for 15 years since the tool was first fabricated in 1998 and resulted in more than 20-fold increase in the amount of papers published in academic journal this year.